N@N

HAWTHORNE, N.J.--([ BUSINESS WIRE ])--Proteonomix, Inc. (OTCBB: PROT) updated the progress of its cosmeceutical business operated by its Proteoderm, Inc, subsidiary under the guidance of recently appointed CEO Jaci Mandil.

Mrs. Mandil is actively moving the company forward with plans for an anticipated third quarter launch of the Proteoderm line of anti-aging skin care products.

• Proteoderm is engaging David Steinberg, a leading industry consultant and author, to work with the company through the start up process.
• Proteoderm is in discussions with packaging suppliers and is moving forward with a short list of package prototypes.
• Proteoderm is also in discussions with a supplier of the proprietary NC-138 material to assure an ample and continuous supply after the product launch.
• Proteoderm is further in discussions with a contract supplier of the base formulation to mix, bottle and deliver the end product.
• Proteoderm has employed Hoplite Digital for graphic design of literature and a redesign of the Proteoderm website.
• Finally, a budget has been established and the funds allocated to perform the product launch.

Mrs. Mandil stated that aWe are moving forward with plans for our anticipated third quarter launch. Novel packaging is being developed and we have refined our product offering significantly for the skin and eye cream products. We are further considering the development of a male skin care product line. We will continue to work to bring it all together and look forward to offering first sales through a dermatologist network.a

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products, which will be available in select U.S. physician offices beginning September 2012. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease, with plans to file an IND application in the 2012 second quarter for post-myocardial infarction treatment. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at [ www.proteonomix.com ] and [ www.proteoderm.com ].

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.